Abstract
Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have